arrow
K

Kathleen N. Moore

stephenson cancer center
H指数:84
被引数:4.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase IB trial of the BMI-1 inhibitor unesbulin plus neoadjuvant paclitaxel-carboplatin in advanced ovarian cancer

BMI-1抑制剂unesbulin联合新辅助紫杉醇-卡铂在晚期卵巢癌中的IB期临床试验

2026-08-250
OA
Associations between molecular classification and response to intrauterine levonorgestrel therapy in patients with medically managed endometrial cancer and endometrial intraepithelial neoplasia: a multicenter Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study

分子分型与接受宫内左炔诺孕酮治疗的患者中子宫内膜癌和子宫内膜上皮内瘤变的治疗反应之间的关联:一项多中心子宫内膜癌分子靶向治疗(ECMT2)联盟研究

2026-04-290
PRE
Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer

DUO-E研究结果的简明总结:在晚期子宫内膜癌患者中给予durvalumab,联合或不联合olaparib。

2026-04-060
PRE
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

阿伐木单抗与德法他尼联用治疗复发性低级别浆液性卵巢癌:ENGOT-OV60/GOG-3052/RAMP 201 II期临床试验的通俗语言总结

2025-12-120
OAAI
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary

I期可行性试验:评估紫杉醇/卡铂联合Galunisertib(一种抑制1型TGF-B受体激酶域的小分子抑制剂)在初诊、持续性或复发性子宫或卵巢癌肉瘤患者中的疗效。

2025-11-050
PRE
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer

mirvetuximab soravtansine(一种靶向叶酸受体α(FRα)的抗体偶联药物,ADC)与pembrolizumab联合治疗铂耐药性卵巢癌患者的安全性与有效性

2025-07-220
PRE
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution

GOG基金会和EVA/LACOG合作伙伴关系:一个用于临床 trial 执行的协作战略联盟

2025-06-270
PRE
Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc’s Scholar Career Development Award and New Investigator Program

扩大致力于妇科肿瘤研究的临床试验研究者队伍:GOG Foundation, Inc.的学者职业发展奖和新研究者项目

2025-06-210
OAAI
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results

Veliparib联合一线化疗及作为卵巢癌的维持治疗:最终总生存期及疾病相关症状结果

2025-06-170
PRE
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial

在预后不良的卵巢癌中,添加免疫检查点抑制剂atezolizumab到一线化疗对无进展生存期的影响:IMagyn050试验的一项回顾性分析

2025-06-010
OAAI
Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US (vol 19, e0307282, 2024)

宫颈癌中的健康差异:估算疾病负担的地理变化及其与美国关键社会经济和人口因素的相关性(卷19,e0307282,2024)

2025-05-200
OA
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy

低风险宫颈癌患者在接受单纯性、改良式或根治性子宫切除术后的长期生存情况

2025-05-150
OA
The dynamic immune behavior of primary and metastatic ovarian carcinoma

原发性和转移性卵巢癌的动态免疫行为

2025-04-250
OA